Glaukomani bartaraf etish nega yetarli emas: ko‘rish qobiliyatini saqlashdagi to‘siqlar va cheklovlar

Annotasiya

Glaukoma - muhim optik neyropatiya bo‘lib, butun dunyo bo‘ylab qaytarilmas ko‘rlik holatlarining asosiy sababchisidir. Ko‘z ichi bosimini (KIB) samarali nazorat qilishga qaramay, ko‘plab bemorlar KIBdan tashqari omillar tufayli ko‘rish qobiliyatini yo‘qotishda davom etmoqdalar. Ushbu sharh glaukomaning murakkab tabiatini, jumladan qon tomir, neyrodegenerativ va genetik jihatlarini o‘rganib chiqadi, shu bilan birga mavjud davolash usullarining cheklovlarini ham ko‘rib chiqadi. Kech tashxis qo‘yish, davolanish rejimiga rioya qilmaslik va ko‘ruv nervining qaytarilmas shikastlanishi kabi asosiy muammolar, shuningdek sog‘liqni saqlash tizimidagi tengsizlik va ijtimoiy-iqtisodiy omillar kabi tizimli masalalar tahlil qilinadi. Neyroprotektiv davolash usullari, sun’iy intellekt yordamida takomillashtirilgan diagnostika, individual tibbiyot va ko‘rish qobiliyatini tiklash kabi innovatsion yondashuvlar bemorlar natijalarini yaxshilash imkoniyatini taqdim etadi. Shunday bo‘lsa-da, klinik amaliyotda sezilarli kamchiliklar saqlanib qolmoqda. Bu esa glaukomani davolashda ko‘rish qobiliyatini saqlashga ustuvor ahamiyat berishni talab etadigan tubdan o‘zgarishni taqozo etadi.

Manba turi: Jurnallar
Yildan beri qamrab olingan yillar 2020
inLibrary
Google Scholar
Chiqarish:
CC BY f
464-469
29

Кўчирилди

Кўчирилганлиги хақида маълумот йук.
Ulashish
Muhammadiyev, S., Eminov, R., & Nishonov, E. (2025). Glaukomani bartaraf etish nega yetarli emas: ko‘rish qobiliyatini saqlashdagi to‘siqlar va cheklovlar. in Library, 1(2), 464–469. Retrieved from https://inlibrary.uz/index.php/archive/article/view/97291
Crossref
Сrossref
Scopus
Scopus

Annotasiya

Glaukoma - muhim optik neyropatiya bo‘lib, butun dunyo bo‘ylab qaytarilmas ko‘rlik holatlarining asosiy sababchisidir. Ko‘z ichi bosimini (KIB) samarali nazorat qilishga qaramay, ko‘plab bemorlar KIBdan tashqari omillar tufayli ko‘rish qobiliyatini yo‘qotishda davom etmoqdalar. Ushbu sharh glaukomaning murakkab tabiatini, jumladan qon tomir, neyrodegenerativ va genetik jihatlarini o‘rganib chiqadi, shu bilan birga mavjud davolash usullarining cheklovlarini ham ko‘rib chiqadi. Kech tashxis qo‘yish, davolanish rejimiga rioya qilmaslik va ko‘ruv nervining qaytarilmas shikastlanishi kabi asosiy muammolar, shuningdek sog‘liqni saqlash tizimidagi tengsizlik va ijtimoiy-iqtisodiy omillar kabi tizimli masalalar tahlil qilinadi. Neyroprotektiv davolash usullari, sun’iy intellekt yordamida takomillashtirilgan diagnostika, individual tibbiyot va ko‘rish qobiliyatini tiklash kabi innovatsion yondashuvlar bemorlar natijalarini yaxshilash imkoniyatini taqdim etadi. Shunday bo‘lsa-da, klinik amaliyotda sezilarli kamchiliklar saqlanib qolmoqda. Bu esa glaukomani davolashda ko‘rish qobiliyatini saqlashga ustuvor ahamiyat berishni talab etadigan tubdan o‘zgarishni taqozo etadi.


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

464

WHY ADDRESSING GLAUCOMA IS INSUFFICIENT: OBSTACLES AND

CONSTRAINTS IN VISION CONSERVATION

Mukhammadiyev Sobirjon Uchkunjon ugli

Assistant of Traumatology and Orthopedics Department, FMIOPH, Fergana, Uzbekistan

Eminov Ravshanjon Ikromjon Ugli

Assistant of Faculty and Hospital Surgery Department, FMIOPH, Fergana, Uzbekistan

Nishanov Eshonkhoja Khamedkhoja ugli

Assistant of Traumatology and Orthopedics Department, FMIOPH, Fergana, Uzbekistan

eshonxojanishonov@gmail.com

Abstract:

Glaucoma, a significant optic neuropathy, is a principal contributor to irreversible

blindness worldwide. Despite effective management of intraocular pressure (IOP), many

patients continue to suffer vision loss due to factors beyond IOP. This review investigates the

complex nature of glaucoma, encompassing vascular, neurodegenerative, and genetic elements,

while also addressing the limitations of existing treatment modalities. Principal obstacles such

as late diagnosis, adherence to therapy, and irreversible optic nerve damage, as well as systemic

issues like healthcare inequities and socioeconomic influences, are scrutinized. Innovative

approaches, including neuroprotective treatments, AI-enhanced diagnostics, personalized

medicine, and vision rehabilitation, present potential improvements in patient outcomes.

Nevertheless, considerable deficiencies in clinical implementation persist, requiring a

fundamental shift in glaucoma management towards prioritizing vision conservation.

Keywords:

glaucoma, vision preservation, neuroprotection, intraocular pressure, personalized

medicine.

Introduction.

Glaucoma is a neurodegenerative condition resulting in the loss of retinal

ganglion cells and optic nerve degeneration, causing irreversible vision loss. Management

primarily focuses on intraocular pressure control, the only modifiable risk factor shown to

mitigate disease progression. Pharmacological options, like Rho kinase inhibitors, face

challenges such as patient adherence and side effects. Surgical methods have shifted towards

minimally invasive approaches that require further validation through extensive trials. Despite

these developments, some patients experience vision loss even with controlled intraocular

pressure, indicating additional factors in disease progression. This has sparked interest in

neuroprotective strategies aimed at preserving retinal ganglion cells and optic nerve integrity

independently of intraocular pressure management. Although animal studies show promise, no

neuroprotective medications have received clinical approval. Future investigations are directed

towards IOP-independent therapies, including gene and stem cell interventions, as well as

personalized medical strategies to tackle glaucoma's intricate pathophysiology.

Understanding glaucoma beyond IOP.

Intraocular pressure (IOP) is a pivotal modifiable risk

factor in glaucoma treatment, targeting its reduction to avert optic nerve damage. However,

disease progression persists in many patients despite adequate IOP management, suggesting

additional contributing factors. Vascular parameters, including mean ocular perfusion pressure

(MOPP) and blood pressure variability, notably influence normal tension glaucoma (NTG)

progression. Research indicates that nocturnal blood pressure declines and MOPP fluctuations

are associated with increased visual field impairment, implicating vascular dysregulation in the

disease's advancement. Furthermore, glaucoma exhibits shared pathophysiological traits with

neurodegenerative disorders such as Alzheimer's and Parkinson's, characterized by apoptosis,

disrupted axonal transport, and oxidative stress, which IOP-lowering treatments do not address.

Genetic factors also play a role in glaucoma risk, with specific genetic markers correlating with

heightened vulnerability. The advancing comprehension of IOP necessitates extensive


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

465

monitoring, including ambulatory measurements, to identify fluctuations beyond office settings

that correlate with disease progression independent of average IOP. This comprehensive

perspective emphasizes the integration of vascular, neurodegenerative, and genetic factors into

glaucoma management strategies to enhance patient outcomes beyond mere IOP control.

Challenges in vision preservation.

Preserving vision in glaucoma patients is challenging due

to the disease's asymptomatic nature leading to late diagnosis. Glaucoma, a progressive optic

neuropathy, involves retinal ganglion cell loss and visual field deterioration, with elevated

intraocular pressure as a significant modifiable risk factor. The asymptomatic progression

complicates early detection, necessitating careful longitudinal monitoring to discern structural

or functional changes. Current therapies target intraocular pressure management but often fail

to prevent disease progression, as they do not address underlying optic nerve

neurodegeneration. The irreversibility of optic nerve damage complicates treatment, as lost

vision cannot be restored. Monitoring progression is difficult due to glaucoma's slow and

variable nature, requiring clinical judgment to balance early intervention against overtreatment

risks. Patient adherence to IOP-lowering therapies is low, often resulting in medication

discontinuation and increased disease progression risk. The emotional and functional burden on

patients is considerable, necessitating comprehensive self-management support that

encompasses health information and daily living assistance. These challenges highlight the

urgent need for improved diagnostic strategies, adherence support, and neuroprotective

therapies to enhance vision preservation in glaucoma patients.

Year Authors

Challenges

Impact

On

Vision

Preservation

2022

Thomas

V.

Johnson,

Adriana Di Polo,

José-Alain

Sahel, Joel S.

Schuman

- Late diagnosis of neurodegenerative

conditions affecting the retina and

optic nerve poses a significant

challenge,

as

it

limits

timely

intervention and the potential for

preserving

vision

in

affected

individuals.

- The key challenge faced in

vision preservation despite

effective glaucoma treatment

is the presence of clinical

barriers such as late diagnosis,

gaps in health care access, and

incomplete

therapeutic

responses

to

existing

therapies.

2023

Shweta Tripathi,

Kinjal

Yogeshbhai

Trivedi, Purvi R

Bhagat

- Medication adherence is a major

issue in the management of glaucoma

patients, with numerous obstacles

identified in the literature that affect

patients' compliance, including drug-

related

factors,

patient-doctor

interactions, and individual patient

behaviors and lifestyles.

- Medication adherence is a

major challenge in glaucoma

management, as patients who

do not take their medications

as directed risk not achieving

the

expected

treatment

outcomes, which can lead to

irreversible vision loss.

2023

Godswill

I

Nathaniel, Ukwu

A. Eze

- The challenges related to surgeries

and the preservation of the conjunctiva

are influenced by the surgeon's skills

and the choice of surgical site, which

can vary across different procedures.

Additionally, recommended alternative

delivery

systems

for

glaucoma

management are often not readily

available globally due to skill gaps,

- The long-term use of topical

antiglaucoma

medications,

particularly those containing

preservatives, can exacerbate

ocular

surface

diseases,

leading

to

chronic

conjunctival

inflammation

and potentially compromising

the success of glaucoma


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

466

and even when available, they may be

inaccessible due to high costs and lack

of insurance coverage in lower-income

economies.

filtration surgeries, which are

crucial

for

vision

preservation.

2023

Yiting

Hua,

Hujie

Lu,

Jingyao

Dai,

Yewei

Zhou,

Wenzhe Zhou,

Aisun

Wang,

Yanyan

Chen,

Youping Liang

- Patients with primary glaucoma face

challenges in becoming experts in their

condition,

which

involves

understanding the complexities of

glaucoma and its management, leading

to feelings of inadequacy and

frustration.

- Patients with primary

glaucoma face challenges in

becoming

experts

in

managing their condition,

which can impact their ability

to preserve vision despite

effective treatment.

2023

- Patients with primary glaucoma face

challenges in becoming knowledgeable

about their condition, including

understanding

the

disease's

characteristics and proper techniques

for applying eye drops. Many patients

reported a lack of prior knowledge

about glaucoma, which hindered their

ability to manage their health

effectively.

- Patients with primary

glaucoma face challenges

such as managing negative

emotions and adapting to

daily life changes, which can

hinder

their

ability

to

effectively engage in self-

management and ultimately

impact vision preservation

despite treatment.

2023 s.y. h

- One of the significant challenges in

diagnosing

glaucoma

is

the

considerable

variation

in

the

appearance of the optic disk and

peripapillary region in normal eyes,

which complicates the early detection

of the disease. This variability can lead

to difficulties in establishing a clear

diagnosis, especially in patients with

anomalous optic disks or other ocular

characteristics such as high myopia.

- One of the key challenges in

vision preservation despite

effective glaucoma treatment

is the difficulty in accurately

diagnosing glaucoma in its

early stages due to significant

variations in the appearance

of the optic disk and

peripapillary region in normal

eyes, which can lead to

uncertainty

in

treatment

decisions.

2023

Luciano

Quaranta,

Alessio Novella,

Mauro

Tettamanti, Luca

Pasina, Robert

N.

Weinreb,

Alessandro

Nobili

- Many patients with glaucoma

experience forgetfulness, which is

reported as the primary reason for

noncompliance with their medication

regimen. This forgetfulness can be

exacerbated by the complexity of the

medication regimen, especially for

those on multiple medications, making

it difficult for patients to remember to

take their eye drops consistently.

- Poor adherence to prescribed

glaucoma

therapy

significantly hampers vision

preservation, as it is closely

related to disease progression

and increased rates of visual

field loss among patients.

2024 Marcelo Iran de

Souza Coelho

- The patient experienced a steroid-

induced elevation in intraocular

pressure (IOP) following endoscopic

cyclophotocoagulation (ECP) in the

right eye, which complicated the

management of his primary open-angle

- Despite effective glaucoma

treatment,

the

patient

experienced adverse reactions

to medications, such as

latanoprost, which led to

complications

like

eye


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

467

Table 1.

Challenges in glaucoma management and vision preservation.

Emerging strategies and research directions.

Emerging strategies in glaucoma management

emphasize neuroprotection, diagnostic advancements, personalized medicine, and vision

rehabilitation. Neuroprotective approaches are essential as conventional intraocular pressure

reduction methods are insufficient for preventing retinal ganglion cell degeneration.

Investigations into pharmacological agents like brimonidine and memantine, along with novel

technologies such as stem cell and gene therapies, are underway to safeguard and regenerate

retinal ganglion cells. In diagnostics, artificial intelligence significantly enhances glaucoma

care through improved early detection and personalized treatment. AI algorithms demonstrate

high precision in evaluating imaging techniques, facilitating early diagnosis and prognostic

assessments. Furthermore, AI enhances teleophthalmology, broadening access to specialized

care and enabling tailored treatment regimens. The incorporation of biomarkers, including

genetic and metabolic indicators, presents a promising pathway for early diagnosis and

monitoring of disease progression. Personalized medicine, propelled by AI and biomarker

integration, seeks to customize interventions based on individual patient profiles, optimizing

therapeutic efficacy and reducing adverse effects. Collectively, these advancements offer

optimism for enhanced glaucoma management and vision restoration, although further

investigation is required to substantiate these methods and incorporate them into clinical

settings.

Barriers to vision preservation.

Systemic challenges pertaining to the effective preservation

of vision in glaucoma patients are intricate and multifaceted, involving a confluence of

socioeconomic determinants, disparities in healthcare access, and constraints related to research

funding and the clinical application of findings. The socioeconomic status of individuals plays

a crucial role in determining access to glaucoma-related care, as elements such as insurance

eligibility, educational attainment, income levels, and marital circumstances significantly affect

glaucoma (POAG). This necessitated

the use of minimally invasive

procedures to address the elevated IOP

in the left eye.

swelling

and

discomfort,

highlighting challenges in

maintaining

vision

preservation during treatment.

2024

Siddharth

Bhargava,

Lauren Mason,

Constance

Okeke

- Challenges in implementing effective

screening

strategies

for

family

members of glaucoma patients include

slow disease progression, which can

lead to delayed diagnosis and

treatment, as well as healthcare

accessibility issues that may prevent

high-risk individuals from receiving

timely screenings.

- The slow progression of

glaucoma

and

the

asymptomatic nature of the

disease until late stages pose

significant

challenges

to

timely intervention and vision

preservation,

even

with

effective treatment options.

2024

Ghazi O. Bou

Ghanem, Lauren

K.

Wareham,

David J. Calkins

- The anatomical structure of the optic

nerve head varies significantly between

different species, such as rodents,

nonhuman primates, and humans,

which complicates the translation of

preclinical

findings

to

clinical

applications in humans.

- Despite effective glaucoma

treatments aimed at managing

intraocular pressure, many

patients

continue

to

experience vision loss due to

the

neurodegeneration

of

retinal

ganglion

cells,

highlighting the challenge of

addressing the underlying

disease mechanisms directly.


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

468

both diagnosis and adherence to prescribed treatment regimens. Furthermore, these

socioeconomic variables are intensified by racial inequities, with empirical studies revealing

that African American patients and those residing in economically disadvantaged areas are

disproportionately impacted by more severe manifestations of glaucoma. Healthcare

inequalities are further aggravated by systemic obstacles to accessing necessary medications, as

a notable proportion of glaucoma prescriptions generated electronically are not fulfilled due to

complications such as prior authorization requirements and limitations in insurance coverage.

Moreover, the prevailing lack of awareness and education surrounding glaucoma, particularly

within underserved populations, contributes to delays in diagnosis and treatment initiation,

thereby exacerbating the overall progression of the disease. In spite of the advancements made

in diagnostic and therapeutic technologies, these disparities remain entrenched, underscoring

the urgent need for targeted interventions, including teleophthalmology and the application of

artificial intelligence, to enhance early detection and management practices. Effectively

addressing these systemic challenges necessitates a concerted collaboration among healthcare

practitioners, policymakers, and researchers to formulate strategies that not only enhance

access to care but also improve patient education and ensure an equitable distribution of

healthcare resources.

Conclusion.

The management of glaucoma has evolved considerably, especially in the

regulation of intraocular pressure. Nonetheless, the ongoing visual impairment encountered by

numerous patients underscores the necessity to consider determinants that extend beyond

intraocular pressure. Multifaceted factors such as vascular dysregulation, neurodegeneration,

and genetic susceptibility are instrumental in the advancement of the disease, while systemic

obstacles and the limitations of therapeutic interventions exacerbate the difficulties associated

with vision preservation. Future investigative efforts should prioritize neuroprotective and

regenerative methodologies, precision diagnostic techniques, and the implementation of

personalized medicine. Furthermore, tackling healthcare disparities and enhancing patient

education are imperative for ensuring equitable access to efficacious treatment. An all-

encompassing strategy that amalgamates these approaches will be crucial in bridging the divide

between therapeutic interventions and sustained vision conservation.

References:

1.

Abjalilovna, M. S. (2024). GIPOKSIYA VA GIPOKSIYAGA MOSLASHUV

MEXANIZMLARI. THE THEORY OF RECENT SCIENTIFIC RESEARCH IN THE FIELD

OF PEDAGOGY, 2(21), 329-332.

2.

Alpersovna, M. Y., & Erkinjon o‘g‘li, L. A. (2025). ALKOGOLLI PANKREATIT:

SABABLARI, BELGILARI VA DAVOLASH USULLARI. ZAMONAVIY TA'LIMDA FAN

VA INNOVATSION TADQIQOTLAR JURNALI, 3(2), 17-22.

3.

Gochadze, A. L., & Irgasheva, M. D. (2016). Using clinical interactive games on

lessons in medical colleges. Актуальные проблемы гуманитарных и естественных наук, (5-

6), 26-28.

4.

Ravshan o'g'li, K. S., & Mavlonjon o’g’li, Q. J. (2024). Review Of The Use Of

Tomosynthesis For The Diagnosis Of Injuries And Diseases Of The Musculoskeletal

System. Frontiers in Health Informatics, 13(6).

5.

Sadriddin, P., Akhtam, R., Mahbuba, A., Sherzod, K., Gulnora, R., Orif, N., ... &

Dilshod, D. (2025). Dual-Ligand Liposomes Nano carrier with Cisplatin and Anti-PD-L1

siRNA in Head and Neck Squamous Cell Carcinoma: A Review. Journal of

Nanostructures, 15(1), 292-300.

6.

USING PRP IN THE TREATMENT OF ORTHOPEDIC DISEASES. (2025).

International Journal of Medical Sciences, 5(05), 209-211.

https://doi.org/10.55640/

7.

Xamedxuja o‘g‘li, N. E. (2023). Pathogenetic Mechanisms of the Development of

Severe Functional Disorders in Injuries of the Calf-Acorn Joint. SCIENTIFIC JOURNAL OF


background image

ILM FAN YANGILIKLARI KONFERENSIYASI

MAY

ANDIJON,2025

469

APPLIED

AND

MEDICAL

SCIENCES,

2(11),

427–429.

Retrieved

from

https://sciencebox.uz/index.php/amaltibbiyot/article/view/8628

8.

Xamedxuja o‘g‘li, N. E. IMPROVEMENT OF TREATMENT METHODS FOR

CALF-ASIK JOINT INJURIES.

9.

Иргашева,

М.

(2025).

Симуляция

в

клиническом

сестринском

образовании. Общество и инновации, 6(2/S), 107-112.

10.

Латибжонов, А., & Умарова, С. (2023). Технологии искусственного интеллекта в

медицине. in Library, 1(1).

11.

Мирзажонова, C. A., Расулова, М. Т., & Ганижонов, П. Х. ИЗМЕНЕНИЯ

ПРОЦЕССА ГИПОКСИИ ОРГАНИЗМА ПРИ ГЕМИЧЕСКОЙ АНЕМИИ.

12.

Мусаева,

Ю.

А.

(2025).

АЛКОГОЛЛИ

ПАНКРЕАТИТДА

ЛИМФА

ТУГУНЛАРИНИНГ ГИСТОКИМЁВИЙ ЎЗГАРИШЛАРИ. MODERN EDUCATIONAL

SYSTEM AND INNOVATIVE TEACHING SOLUTIONS, 1(7), 29-31.

13.

Туйчибеков, Ш. (2023). Риск смертности при применении НПВС у детей. in

Library, 1(1), 67-71.

14.

Туйчибеков, Ш., & Нишонов, Е. (2024). Морфологические основы практических

рекомендаций по конфокальным морфометрическим показателям повреждений

хвоста. in Library, 2(2), 14-17.

15.

Тўхтаев, Ж. Т., Ботиров, Н. Т., & Нишонов, Э. Х. (2023). Болдир-ошиқ бўғими

шикастланишларини ташхислаш ва даволаш. Zamonaviy tibbiyot jurnali (Журнал

современной медицины), 1(1), 27-39.

16.

Хомидчонова, Ш. Х., & Мирзажонова, С. А. (2023). Основные Методы

Определения Состава Тела. Miasto Przyszłości, 36, 181-185.

Bibliografik manbalar

Abjalilovna, M. S. (2024). GIPOKSIYA VA GIPOKSIYAGA MOSLASHUV MEXANIZMLARI. THE THEORY OF RECENT SCIENTIFIC RESEARCH IN THE FIELD OF PEDAGOGY, 2(21), 329-332.

Alpcrsovna, M. Y., & Erkinjon o‘g‘li, L. A. (2025). ALKOGOLLI PANKREATIT: SABABLARI, BELGILARI VA DA VOLASH USULLARI. ZAMONAVIY TA’LIMDA FAN VA INNOVATSION TADQIQOTLAR JURNALI, 3(2), 17-22.

Gochadze, A. L., & Irgasheva, M. D. (2016). Using clinical interactive games on lessons in medical colleges. Актуальные проблемы гуманитарных и естественных наук, (5-6), 26-28.

Ravshan o’g’li, К. S., & Mavlonjon o’g'li, Q. J. (2024). Review Of The Use Of Tomosynthesis For The Diagnosis Of Injuries And Diseases Of The Musculoskeletal System. Frontiers in Health Informatics, 13(6).

Sadriddin. P., Akhtam, R., Mahbuba, A., Sherzod, K., Gulnora. R., Orif, N., ... & Dilshod, D. (2025). Dual-Ligand Liposomes Nano carrier with Cisplatin and Anti-PD-LI siRNA in Head and Neck Squamous Cell Carcinoma: A Review. Journal of Nanostructures, 15(1), 292-300.

USING PRP IN THE TREATMENT OF ORTHOPEDIC DISEASES. (2025). International Journal of Medical Sciences, 5(05), 209-211. https://doi.org. 10.55640/

Xamedxuja o‘g‘Ii, N. E. (2023). Pathogenetic Mechanisms of the Development of Severe Functional Disorders in Injuries of the Calf-Acorn Joint. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 2(11), 427-429. Retrieved from https://sciencebox.uz/index.php/amaltibbiyot/article/view/8628

Xamedxuja o‘g‘li, N. E. IMPROVEMENT OF TREATMENT METHODS FOR CALF-ASIK JOINT INJURIES.

Иргашева, M. (2025). Симуляция в клиническом сестринском образовании. Общество и инновации, 6(2/S), 107-112.

Латибжонов, А., & Умарова, С. (2023). Технологии искусственного интеллекта в медицине, in Library, 1(1).

Мирзажонова, С. А., Расулова, М. Т., & Ганижонов, П. X. ИЗМЕНЕНИЯ ПРОЦЕССА ГИПОКСИИ ОРГАНИЗМА ПРИ ГЕМИЧЕСКОЙ АНЕМИИ.

Мусаева. Ю. А. (2025). АЛКОГОЛЛИ ПАНКРЕАТИТДА ЛИМФА ТУГУНЛАРИНИНГ ГИСТОКИМЁВИЙ УЗГАРИШЛАРИ. MODERN EDUCATIONAL SYSTEM AND INNOVATIVE TEACHING SOLUTIONS, 1(7), 29-31.

Туйчибсков, Ш. (2023). Риск смертности при применении НПВС у детей, in Library, 1(1), 67-71.

Туйчибеков, III., & Нишонов, Е. (2024). Морфологические основы практических рекомендаций по конфокальным морфометрическим показателям повреждений хвоста, in Library, 2(2), 14-17.

Тухтасв, Ж. Т., Ботиров, Н. Т., & Нишонов, Э. X. (2023). Болдир-ошик бугими шикастланишларини ташхислаш ва даволаш. Zamonaviy tibbiyot jurnali (Журнал современной медицины), 1(1), 27-39.

Хомидчонова, Ш. X., & Мирзажонова, С. А. (2023). Основные Методы Определения Состава Тела. Miasto Przyszlosci, 36, 181-185.